within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX05_Pidotimod;
model Pidotimod 
   extends Pharmacolibrary.Drugs.ATC.L.L03AX05;

  annotation(Documentation(
    info ="<html><body><p>Pidotimod is a synthetic dipeptide immunostimulant that modulates both innate and adaptive immune responses, mainly used in the prevention and treatment of recurrent respiratory tract infections, particularly in children and elderly individuals. It is approved in several countries for this indication but is not universally licensed worldwide.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers, oral administration, single dose pharmacokinetics.</p><h4>References</h4><ol><li><p>Zhang, R, et al., &amp; Hao, Z (2018). Pharmacokinetics of pidotimod in broiler chickens by UHPLC-MS/MS after oral and intravenous administration. <i>Biomedical chromatography : BMC</i> 32(3) –. DOI:<a href=&quot;https://doi.org/10.1002/bmc.4130&quot;>10.1002/bmc.4130</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29105801/&quot;>https://pubmed.ncbi.nlm.nih.gov/29105801</a></p></li><li><p>Mailland, F, et al., &amp; Silingardi, S (1994). Pharmacokinetics and oral bioavailability of pidotimod in humans. <i>Arzneimittel-Forschung</i> 44(12A) 1465–1469. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7857343/&quot;>https://pubmed.ncbi.nlm.nih.gov/7857343</a></p></li><li><p>Coppi, G, &amp; Silingardi, S (1994). Pharmacokinetics of pidotimod in rats and dogs. <i>Arzneimittel-Forschung</i> 44(12A) 1460–1464. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7857342/&quot;>https://pubmed.ncbi.nlm.nih.gov/7857342</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Pidotimod;
